KEY GUIDANCE, FROM 2023 ONWARDS:

• The cost of COVID-19 vaccine doses in excess of domestic supply donated to developing countries does not count in ODA, unless there is a direct request for donation by authorities of developing countries or international health institutions or mechanisms such as COVAX or WHO.
• Ancillary costs incurred by donors when donating their surpluses (additional costs associated to logistics, transport, etc.) can be counted in ODA.

SAFEGUARDS

• Members should explain in their reporting why they use vaccine doses in excess of domestic supply (and not other means of support such as the provision of funding for the purchase of vaccines).
• For the purpose of ODA reporting, the cost of each dose should correspond to the latest average price as determined and shared by Gavi, i.e. USD 6.66 per dose. For the sake of ODA integrity, members should verify the aggregate ODA figure reported for donations against their actual outlay in any given year and make a downward adjustment if needed, in order not to overstate their donations.
• Expired doses should not be counted as ODA and donated doses should have a shelf life of a minimum six months upon arrival in-country.

For more details about this guidance, contributions to specific facilities and cooperation with health research institutions, please refer to our Frequently asked questions.

ODA to COVID-19 response: based on 2022 final data

Key resources:

Official development assistance

Building a resilient recovery - Emerging stronger from the COVID-19 pandemic

Blog on Covid-19 vaccines and official development assistance

COVID-19 Global Pandemic: Joint Statement by the OECD Development Assistance Committee